AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02246933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PUFA Diet
Description: The 7-day diet will consist of 50% carbohydrate, 15% protein, and 35% fat. 21% of total energy will be poly-unsaturated fatty acids, 9% mono-unsaturated fatty acids, and 5% saturated fatty acids.
Study NCT02246933 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Diet
Description: The 7-day diet will consist of 50% carbohydrate, 35% fat, and 15% protein. Furthermore, 7% of total energy will be poly-unsaturated fatty acids, 15% of total energy will be mono-unsaturated fatty acids, and 13% of total energy will be saturated fatty acids.
Study NCT03904654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Description: MBCT is an evidence-based psychotherapy which combines mindfulness skills with cognitive therapy strategies.
Study NCT03630848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effect of Protein on Blastocyst Development
Description: Embryo Development Related to The Protein Concentration
Study NCT01500980 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P. falciparum infection
Description: P. falciparum (NF54 strain) infection delivered by the bites of 12 - 15 infected A. stephensi mosquitos
Study NCT01500980 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: P. falciparum infection
Description: P. falciparum (NF54 strain) infection delivered by the bites of 12 - 15 infected A. stephensi mosquitos
Study NCT01500980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Weekly chloroquine dosing (600 mg loading dose, 300 mg thereafter)
Study NCT01500980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Weekly chloroquine dosing (600 mg loading dose, 300 mg thereafter)
Study NCT01500980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Primaquine (45 mg) on day 2 or 3 post ITV infection
Study NCT01500980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Primaquine (45 mg) on day 2 or 3 (pending results of pilot study) post ITV infection
Study NCT01500980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: Primaquine (45 mg) on day 2 or 3 (pending results of pilot study) post ITV infection
Study NCT04030312 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bottle Supplementation--Commercially-Sterilized Donor Human Milk
Description: Supplementation by bottle with 20-calorie-per-ounce commercially-sterilized donor human milk (up to 15 ml, up to two times) for infants meeting hypoglycemia criteria and randomized to this treatment arm.
Study NCT04030312 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bottle Supplementation--Standard Infant Formula
Description: Supplementation by bottle with 20-calorie-per-ounce standard infant formula (up to 15 ml, up to two times) for infants meeting hypoglycemia criteria and randomized to this treatment arm.
Study NCT04398836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Exclusive Enteral Nutrition
Description: Mulnourished patients will drink an enteral polymeric formula suited to their energy expenditure calculated by 25-30 kcal/kg and at least 1 gr/kg of protein, a minimum of 1500 ml (1500 kcal, 54 gr of protein). The amount of formula to achieve nutritional requirements are based on body weight, but the average intake is of 6-8 cups of formula (36-48 scoops of formula mixed with 1260-1680 ml of water to achieve a concentration of 1 kcal per ml). During this period patients will be guided to avoid eating and drinking anything but the enteral formula. The formula will be supplied to the patients by the investigators. The formula used for this study will be VITAL - suitable for people with disease-related malnutrition and malabsorption. Vital 1.5kcal is peptide-based, nutritionally complete formulation for the dietary management of active phase of Crohn's disease. VITAL includes all the nutritional macro and micronutrients and can serve as a sole source of nutrition.
Study NCT04398836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High energy / protein diet.
Description: Mulnourished patients will receive a high energy / protein diet.
Study NCT04398836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard nutrition
Description: Well nurished patients will receive a standard nutrition
Study NCT00771368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: 1 % Gaseous Nitric Oxide, delivered for 30 minutes daily for 3 consecutive days
Study NCT01123655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APLA12
Description: Intervention: Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
Study NCT01123655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
Study NCT00843466 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mild, moisturizing hand cleanser
Description: Hand cleanser ingredient list:~Ammonium Lauryl Sulfate, Ammonium Laureth Sulfate, Cocamide MEA, PEG-5 Cocamide Cocamidopropyl Betaine Sodium Lauroyl Sarcosinate Glycerin Petrolatum Soybean Oil Sodium Hydroxypropyl Starch Phosphate Lauric Acid Lauryl Alcohol PEG-14M Guar hydroxypropyl trimonium chloride DMDM Hydantoin; Iodopropynyl Butylcarbamate Etidronic Acid Tetrasodium EDTA Titanium Dioxide Fragrance Sodium Hydroxide Water
Study NCT04796701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-Home-intervention
Description: x
Study NCT01719653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MiraLAX
Description: MiraLAX consumed as described in each arm.
Study NCT01719653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MiraLAX
Description: MiraLAX consumed as described in each arm.
Study NCT01719653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gatorade
Description: Gatorade consumed as described in each arm.
Study NCT01719653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gatorade
Description: Gatorade consumed as described in each arm.
Study NCT01719653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MoviPrep
Description: MoviPrep consumed as described in each arm.
Study NCT01719653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUPREP
Description: SUPREP consumed as described in each arm.
Study NCT00112749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab
Description: A single infusion of 1mg/kg will be administered.
Study NCT00112749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Assessment
Description: Medical, psychiatric, and immune evaluation.
Study NCT00112749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-report questionnaires
Description: Fatigue Symptom Inventory, Multidimensional Fatigue Symptom Inventory, Hamilton Depression Rating Scale, Beck Depression Inventory II, Hamilton anxiety Rating Scale, Pittsburgh Sleep Quality Index, Brief Pain Inventory, MOS SF-36.
Study NCT00112749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immune Assessment
Description: Proinflammatory cytokines and markers of cytokine activity and lymphocyte subsets and CBC.
Study NCT04460053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurofilament light protein measurement in Isolated limb perfused patients
Description: A prospective feasibility trial measuring neurofilament light protein in peripheral blood as a biomarker for neurotoxicity after isolated limb perfusion.
Study NCT04194164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid intake app
Description: Monitor fluid intake and interdialytic weight gain in patients using the fluid app
Study NCT01566110 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten Free Diet
Description: Subjects assigned to the intervention group will receive a standardized dietary education intervention that will inform subjects and family members of the effects of gluten on the gastrointestinal tract and emphasize the need to adhere to a diet that is gluten-free. This intervention will be delivered by a dietician who is trained in celiac disease and gluten free diet.
Study NCT04896671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise (running on a treadmill)
Description: Participants in the intervention group join a total of 12 treadmill running sessions, two sessions per week and each session for 30 minutes. In each session, every participant will be trained to run for 30 minutes on a treadmill. According to Exercise and Sports Science Australia (ESSA) exercise intensity guidelines, the intensity of running is suggested to be moderate and vigorous (alternating between the two) in this study.
Study NCT01880827 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y
Description: Subjects in the intervention group will be divided into two consecutive surgical groups, RYGB or SG. After the surgery, subjects are controlled in hospital ward for approximately three days.
Study NCT01880827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GIP-infusion
Description: Blood flow and volume during infusion
Study NCT01880827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP-infusion
Description: Blood flow and volume during infusion
Study NCT01880827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: Blood flow and volume during infusion
Study NCT01880827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMS
Description: Blood flow and volume after meal solution
Study NCT01880827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMS
Description: Blood flow and volume after meal solution
Study NCT01880827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Description: as in RYGS group
Study NCT00381628 — intervention group
Intervention type: PROCEDURE
Intervention: epithelial cells and blood lymphocyte extraction
Description: Nasal curettage will be performed from each nostril to obtain nasal epithelial cells. Venipuncture will be performed and up to 60-ml of blood will be obtained from which neutrophils will be isolated.
Study NCT03070873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perigee and Apogee Mesh
Description: The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
Study NCT03070873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gynecare Prolift Mesh
Description: The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
Study NCT03070873 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional Surgery
Description: The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
Study NCT03817281 — intervention group
Intervention type: DEVICE
Intervention: Accuryn Monitoring System
Description: The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
Study NCT04523012 — intervention group
Intervention type: OTHER
Intervention: Seroprevalence of SARS-CoV-2 infection in patients with HIV infection
Description: On inclusion, after information and collection of the non-objection, a blood sample (D0) will be taken during the assessment of the HIV infection (no unplanned sample will be taken) and a control to determine the appearance or the Persistence of antibodies will be made at M6 and M12 always as part of the assessment of HIV infection.
Study NCT00000320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine formulation: liquid vs. tablet
Description: random assignment to liquid buprenorphine or tablet buprenorphine
Study NCT01087060 — intervention group
Intervention type: PROCEDURE
Intervention: partial or radical nephrectomy
Study NCT03581214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No oxygen
Description: No facemask, room air only
Study NCT03581214 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: 10Liters/minute oxygen by facemask
Study NCT01737736 — intervention group
Intervention type: DEVICE
Intervention: Neurokeeper stroke detector
Description: Electrophisoloigcal monitoring
Study NCT01627665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D->R->C+R
Description: one oral dose DABIGATRAN 300 mg -> RIVAROXABAN 40 mg -> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
Study NCT01627665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D->R->C+D
Description: one oral dose DABIGATRAN 300 mg -> RIVAROXABAN 40 mg -> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
Study NCT01627665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R->D->C+D
Description: RIVAROXABAN 40 mg -> one oral dose DABIGATRAN 300 mg -> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
Study NCT01627665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R->D->C+R
Description: RIVAROXABAN 40 mg -> one oral dose DABIGATRAN 300 mg -> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
Study NCT01892332 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: epidural block with lidocaine and fentanyl
Description: The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting concentration of lidocaine was 1.5 % mixed with fentanyl 75 ug. All patients receive 13mL of lidocaine with fentanyl 75ug. The concentration of lidocaine for subsequent patients is determined by the outcome in the previous patient according to up and down sequential allocation in 0.1% increments. In the case of block failure, the concentration of lidocaine was increased by 0.1%.~Conversely, block success resulted in a reduction in concentration by 0.1%.
Study NCT02342626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dashboard
Description: With the health care provider, subjects will use the decision dashboard to augment the discussion of treatment options.
Study NCT01931384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotrophin
Description: luteal phase support using Human chorionic gonadotrophin 1500 IU intramuscular injection will be given on the day of FET and 6 days later.
Study NCT01931384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline intramuscularly on the day of embryo transfer and 5 days after embryo transfer.
Study NCT01207193 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cell injection
Description: injection of mesenchymal cells to bone cyst defect
Study NCT00333528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human butyrylcholinesterase (HuBChE) derived from human plasma
Description: Intramuscular administration
Study NCT00333528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Normal saline
Description: Intramuscular administration
Study NCT01922934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commercial weight loss program
Description: vouchers for Weight Watchers
Study NCT01922934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colorado Weigh
Description: Group behavioral weight loss program
Study NCT01922934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal replacements
Description: Health Management Resources meal replacement products (shakes and entrees)
Study NCT01922934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obesity pharmacotherapy
Description: Phentermine or phentermine-topiramate (Qsymia)
Study NCT01922934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recreation center passes
Description: 1 year pass to a Denver recreation center
Study NCT00889304 — intervention group
Intervention type: DEVICE
Intervention: Position HTO system
Description: open wedge high tibial osteotomy
Study NCT03513952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT03513952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Given IV
Study NCT03513952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy of tumor
Study NCT03513952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy of tumor
Study NCT03513952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and stool samples
Study NCT03513952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood and stool samples
Study NCT03513952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03513952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03513952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glycosylated Recombinant Human Interleukin-7
Description: Given IM
Study NCT03513952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03513952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03513952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03513952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03513952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography and Computed Tomography Scan
Description: Undergo PET/CT
Study NCT03513952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography and Computed Tomography Scan
Description: Undergo PET/CT
Study NCT00851149 — intervention group
Intervention type: DEVICE
Intervention: Sangvia blood sampling system
Description: Blood collected from abdominal aortic repair patients are compared against blood collected from total hip replacement patients
Study NCT00447408 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard hemodialysis dietary instruction
Description: Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments.
Study NCT00447408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral counseling plus PDA-based self-monitoring of diet
Description: Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments. In addition they receive behavioral counseling paired with PDA-based self-monitoring of dietary sodium intake.
Study NCT00492011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 1 mg, tablets, orally, once nightly for 4 nights.
Study NCT00492011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 4 mg, tablets, orally, once nightly for 4 nights.
Study NCT00492011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg, tablets, orally, once nightly for 4 nights.
Study NCT00492011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally, once nightly for 4 nights.
Study NCT03513419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The AMOR Method
Description: The parent resilience training involves a series of eight weekly 90-minute group sessions with up to 8 parents of young children with ASD (4- 10:11 years old) per group, as well as three individual sessions.
Study NCT00846365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 40 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks.
Study NCT00846365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 40 mg and chlorthalidone 12.5, mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 80 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks.